<p xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" id="Par10">In the second temporal segment of the study (December 1, 2021 to September 30, 2022), when the Omicron variant of COVID-19 was prevalent, vaccination against COVID-19 was associated with reduced rates of venous thromboembolism [7 days: 3.6% vs 8.0%; HR&#8201;=&#8201;0.44; 95% CI&#8201;=&#8201;0.33&#8211;0.60 and 30 days: 4.9% vs 9.2%; HR&#8201;=&#8201;0.52; 95% CI&#8201;=&#8201;0.40&#8211;0.68] and acute myocardial infarction [7 days: 4.0% vs 7.7%; HR&#8201;=&#8201;0.51; 95% CI&#8201;=&#8201;0.38&#8211;0.69 and 30 days: 4.6% vs 8.2%; HR&#8201;=&#8201;0.55; 95% CI&#8201;=&#8201;0.41&#8211;0.72]. There was no association with reduced mortality or intracranial hemorrhage in the vaccinated cohort (Table <xref rid="Tab3" ref-type="table">3</xref>).</p>